Axel Le Cesne
About
Axel Le Cesne is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology.
According to data from OpenAlex, Axel Le Cesne has authored 270 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Pulmonary and Respiratory Medicine, 103 papers in Oncology and 79 papers in Gastroenterology. Recurrent topics in Axel Le Cesne's work include Sarcoma Diagnosis and Treatment (200 papers), Gastrointestinal Tumor Research and Treatment (79 papers) and Vascular Tumors and Angiosarcomas (60 papers). Axel Le Cesne is often cited by papers focused on Sarcoma Diagnosis and Treatment (200 papers), Gastrointestinal Tumor Research and Treatment (79 papers) and Vascular Tumors and Angiosarcomas (60 papers). Axel Le Cesne collaborates with scholars based in France, United States and Italy. Axel Le Cesne's co-authors include Jean‐Yves Blay, Sylvie Bonvalot, M. van Glabbeke, Paolo G. Casali, Ian Judson, C. Le Péchoux, Jaap Verweij, Antoîne Italiano, Philippe Terrier and Isabelle Ray‐Coquard and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Axel Le Cesne
255 papers receiving 10.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Axel Le Cesne France | 56 | 7.9k | 4.3k | 2.6k | 2.1k | 2.1k | 270 | 10.6k | ||
| Axel Le Cesne France | 62 | 9.7k 1.2× | 7.1k 1.7× | 2.5k 1.0× | 2.7k 1.3× | 2.2k 1.1× | 265 | 14.6k | ||
| Shreyaskumar Patel United States | 63 | 10.9k 1.4× | 6.0k 1.4× | 2.5k 1.0× | 3.2k 1.5× | 3.5k 1.7× | 260 | 14.7k | ||
| Scott M. Schuetze United States | 43 | 6.4k 0.8× | 3.3k 0.8× | 1.3k 0.5× | 2.0k 0.9× | 1.3k 0.6× | 167 | 8.7k | ||
| Chandrajit P. Raut United States | 52 | 6.0k 0.8× | 4.3k 1.0× | 2.3k 0.9× | 1.1k 0.5× | 3.3k 1.6× | 202 | 9.5k | ||
| Sylvie Bonvalot France | 54 | 9.3k 1.2× | 5.2k 1.2× | 1.5k 0.6× | 3.7k 1.8× | 3.2k 1.5× | 268 | 12.2k | ||
| Jonathan J. Lewis United States | 46 | 6.3k 0.8× | 3.6k 0.8× | 2.2k 0.8× | 2.8k 1.3× | 2.2k 1.0× | 86 | 10.0k | ||
| Maria Dêbiec‐Rychter Belgium | 59 | 7.5k 1.0× | 2.7k 0.6× | 4.2k 1.6× | 2.2k 1.1× | 2.5k 1.2× | 318 | 12.3k | ||
| Angelo Paolo Dei Tos Italy | 67 | 10.9k 1.4× | 6.1k 1.4× | 2.5k 0.9× | 4.5k 2.2× | 3.4k 1.7× | 438 | 17.0k | ||
| Jonathan C. Trent United States | 48 | 5.1k 0.7× | 2.5k 0.6× | 3.5k 1.3× | 1000 0.5× | 2.2k 1.1× | 283 | 8.2k | ||
| Jonathan A. Fletcher United States | 57 | 5.6k 0.7× | 1.7k 0.4× | 2.5k 1.0× | 2.2k 1.1× | 1.8k 0.9× | 129 | 9.5k |
Countries citing papers authored by Axel Le Cesne
Since
Specialization
Citations
This map shows the geographic impact of Axel Le Cesne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Le Cesne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Le Cesne more than expected).
Fields of papers citing papers by Axel Le Cesne
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Axel Le Cesne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Le Cesne. The network helps show where Axel Le Cesne may publish in the future.
Co-authorship network of co-authors of Axel Le Cesne
This figure shows the co-authorship network connecting the top 25 collaborators of Axel Le Cesne. A scholar is included among the top collaborators of Axel Le Cesne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Le Cesne. Axel Le Cesne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Coté, Gregory M., Sant P. Chawla, George D. Demetri, et al.. (2025). SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncology. 21(8). 943–951.
2.
Michot, Audrey, Jean‐Michel Coindre, Valérie Velasco, et al.. (2025). Prognostic prediction in soft-tissue sarcomas using deep learning and digital pathology of tumor and margin areas. Scientific Reports. 15(1). 38534–38534.
3.
Tap, William D., Vivek A. Bhadri, Silvia Stacchiotti, et al.. (2024). Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.. Journal of Clinical Oncology. 42(16_suppl). 11500–11500.
4.
Cesne, Axel Le, Christine Chevreau, Christophe Perrin, et al.. (2023). Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open. 8(3). 101569–101569.
5.
Bonvalot, Sylvie, Nathalie Cozic, Axel Le Cesne, et al.. (2023). Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial. Annals of Surgical Oncology. 30(13). 8653–8659.
6.
Penel, Nicolas, Daniel Orbach, Véronique Minard‐Colin, et al.. (2023). Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age. SHILAP Revista de lepidopterología. 1. 100012–100012.
7.
D’Angelo, Sandra P., Kristen N. Ganjoo, Jean‐Yves Blay, et al.. (2023). The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.. Journal of Clinical Oncology. 41(16_suppl). e14531–e14531.
8.
Duffaud, Florence, Jean‐Yves Blay, Axel Le Cesne, et al.. (2023). Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. British Journal of Cancer. 129(12). 1940–1948.
9.
Martín‐Broto, Javier, Nadia Hindi, Giovanni Grignani, et al.. (2022). Experience with Second-Line Trabectedin in Daily Clinical Practice: Case Studies. Future Oncology. 18(sup30). 23–32.
10.
Bauer, Sebastian, Robin L. Jones, Jean‐Yves Blay, et al.. (2022). Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 40(34). 3918–3928.
11.
Grignani, Giovanni, Axel Le Cesne, & Javier Martín‐Broto. (2022). Trabectedin as Second-Line Treatment in Advanced Soft Tissue Sarcoma: Quality of Life and Safety Outcomes. Future Oncology. 18(sup30). 13–22.
12.
Brodowicz, Thomas, Bernadette Liegl‐Atzwanger, Nicolas Penel, et al.. (2020). Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers. 12(12). 3746–3746.
13.
Bertucci, François, Alexandre de Nonneville, Pascal Finetti, et al.. (2017). The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. Annals of Oncology. 29(2). 459–465.
14.
Casali, Paolo G., Axel Le Cesne, Andrés Poveda, et al.. (2017). Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. Annals of Oncology. 28. v645–v645.
15.
Cesne, Axel Le, M. Ouali, Michael Leahy, et al.. (2014). Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Annals of Oncology. 25(12). 2425–2432.
16.
Italiano, Antoîne, Simone Mathoulin‐Pélissier, Axel Le Cesne, et al.. (2010). Trends in survival for patients with metastatic soft‐tissue sarcoma. Cancer. 117(5). 1049–1054.
17.
Bonvalot, Sylvie, Françoise Rimareix, Sylvain Causeret, et al.. (2009). Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient. Annals of Surgical Oncology. 16(12). 3350–3357.
18.
Lassau, Nathalie, Michele Lamuraglia, D. Vanel, et al.. (2005). Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Annals of Oncology. 16(7). 1054–1060.
19.
Bonvalot, Sylvie, D. Vanel, Philippe Terrier, et al.. (2004). Traitement des récidives des sarcomes rétro-péritonéaux. Bulletin du Cancer. 91(11). 845–852.
20.
Khanfir, K., et al.. (2003). Unusual Problems in Breast Cancer and a Rare Lung Cancer Case. Journal of Clinical Oncology. 21(11). 2216–2218.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Axel Le Cesne Breakdown of academic impact, for papers by Shreyaskumar Patel Breakdown of academic impact, for papers by Scott M. Schuetze Breakdown of academic impact, for papers by Chandrajit P. Raut Breakdown of academic impact, for papers by Sylvie Bonvalot Breakdown of academic impact, for papers by Jonathan J. Lewis Breakdown of academic impact, for papers by Maria Dêbiec‐Rychter Breakdown of academic impact, for papers by Angelo Paolo Dei Tos Breakdown of academic impact, for papers by Jonathan C. Trent Breakdown of academic impact, for papers by Jonathan A. Fletcher